Abstract
Haloperidol is the best-known most worldwide used classic first-generation (typical) antipsychotic, commonly used for positive symptoms of schizophrenia. Besides oral and parenteral forms, a long-acting depot formulation as an injection every 4 weeks is also available. As a high-potency antipsychotic acting as D2 receptor antagonist, it tends to produce significant extrapyramidal side effects. The efficacy in treatment of psychoses was established in numerous randomized, double-blind, placebo-controlled and maintenance studies.
Similar content being viewed by others
References
Adams C, Bergman H, Irving C. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD003082.
Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987;33(1):31–49.
Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev. 2006;19:CD004362.
Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen MR, Marwa ME, AlMounayer N. Haloperidol discontinuation for people with schizophrenia. Cochrane Database Syst Rev. 2019;4:CD011408.
Grange B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17:137–40.
Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27–39.
Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
Khushu A, Powney MJ. Haloperidol for long-term aggression in psychosis. Cochrane Database Syst Rev. 2016;11:CD009830. https://doi.org/10.1002/14651858.CD009830.pub2.
Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P. Persistence of haloperidol in human brain tissue. Am J Psychiatry. 1999;156:885–90.
Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435–56.
Lao KSJ, Wong AYS, Wong ICK, Besag FMC, Chang WC, Lee EHM, Chen EYH, Blais JE, Chan EW. Mortality risk associated with haloperidol use compared with other antipsychotics: an 11-year population-based propensity-score-matched cohort study. CNS Drugs. 2020;34:197–206.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.
Leucht S, Cipriani A, Spineli L, Mavridis D, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.
Lopez-Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009;79:130–41.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
Rasmussen SA, Rosebush PI, Mazurek MF. The relationship between early haloperidol response and associated extrapyramidal side effects. J Clin Psychopharmacol. 2017;37:8–12.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. Int Pharmacopsychiatry. 1982;17:238–46.
Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993;631:191–202.
Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia. CNS Drugs. 2001;15:671–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Laux, G. (2022). Haloperidol in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_127-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_127-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine